Get the Stockscreener App
1.91
7.28%
-0.15
After Hours:
1.91
In 8 Bio Inc stock is traded at $1.91, with a volume of 51,849.
It is down -7.28% in the last 24 hours and up +11.05% over the past month.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
See More
Previous Close:
$2.06
Open:
$2.05
24h Volume:
51,849
Relative Volume:
0.20
Market Cap:
$18.65M
Revenue:
-
Net Income/Loss:
$-19.44M
P/E Ratio:
-0.7185
EPS:
-2.6585
Net Cash Flow:
$-12.71M
1W Performance:
+5.52%
1M Performance:
+11.05%
6M Performance:
-4.50%
1Y Performance:
-71.85%
1-Day Range:
$1.87
$2.05
1-Week Range:
$1.77
$2.11
52-Week Range:
$1.17
$7.50
In 8 Bio Inc Stock (INAB) Company Profile
Name
In 8 Bio Inc
Sector
Industry
Phone
(646) 600-6438
Address
EMPIRE STATE BUILDING, NEW YORK
Compare INAB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
1.91 | 20.12M | 0 | -19.44M | -12.71M | -2.6585 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.49 | 118.41B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
759.05 | 80.02B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
706.03 | 43.52B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.42 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
287.33 | 32.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-24 | Initiated | Laidlaw | Buy |
| Aug-30-22 | Initiated | H.C. Wainwright | Buy |
In 8 Bio Inc Stock (INAB) Latest News
[144] KALA BIO, Inc. SEC Filing - Stock Titan
INmune Bio Receives $8 Consensus Price Target from Analysts - National Today
[8-K] Bio Green Med Solution, Inc. Reports Material Event | BGMS SEC FilingForm 8-K - Stock Titan
CyPath Lung growth accelerates while bioAffinity (NASDAQ: BIAF) posts larger 2025 loss - Stock Titan
Morgan Stanley Smith Barney files Form 144 to sell restricted KALA shares (KALA) - Stock Titan
Adicet Bio (NASDAQ: ACET) outlines 2025 loss and cash runway into 2027 - Stock Titan
Korro Bio (NASDAQ: KRRO) expands RNA-editing pipeline as 2025 net loss deepens - Stock Titan
Layoff Tracker: Vistagen, Evotec, Reckitt Benckiser Downsize, Collectively Affecting Hundreds - BioSpace
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
$180B AI healthcare play: KALA BIO pivots with first agent - Stock Titan
Passage Bio (PASG) pays $4.8M to end long-term Hopewell lab lease - Stock Titan
Korro Bio Raises $85 Million in Private Placement, Adds Investor Registration Rights - TradingView
Korro Bio (KRRO) secures $85M PIPE to extend cash runway into 2028 - Stock Titan
Annovis Bio Stock Price Drops 8.5%What's Next? - National Today
Climb Bio (Nasdaq: CLYM) ends 2025 with $160.7M cash and key 2026 trial readouts ahead - Stock Titan
PALI SEC FilingsPalisade Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
KALA BIO (NASDAQ: KALA) signs exclusive Researgency AI license and $55M Younet option - Stock Titan
Bank license renewal backs BIO-key (NASDAQ: BKYI) biometric growth - Stock Titan
Short Interest in Palisade Bio, Inc. (NASDAQ:PALI) Rises By 20.2% - MarketBeat
CABA SEC FilingsCabaletta Bio, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Entera Bio (NASDAQ: ENTX) refines EB613 Phase 3 osteoporosis trial timeline - Stock Titan
bioAffinity Technologies (NASDAQ: BIAF) shows asthma and COPD diagnostic data - Stock Titan
Passage Bio (NASDAQ: PASG) narrows 2025 loss and advances PBFT02 trial - Stock Titan
Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results - TradingView
IBTROZI launch lifts Nuvation Bio (NUVB) 2025 revenue while losses narrow - Stock Titan
683 Capital reports 5.23% stake in Gossamer Bio | GOSS SEC FilingForm SCHEDULE 13G - Stock Titan
Adicet Bio Inc expected to post a loss of $2.80 a shareEarnings Preview - TradingView
QTTB SEC FilingsQ32 BIO INC 10-K, 10-Q, 8-K Forms - Stock Titan
Belite Bio Inc expected to post a loss of 55 cents a shareEarnings Preview - TradingView
INmune Bio (NASDAQ: INMB) outlines RDEB and Alzheimer’s trial paths - Stock Titan
Inmune Bio furnishes corporate presentation detailing CORDStrom and XPro1595 development plans - TradingView
Zura Bio (ZURA) revises Ogier legal opinion and consent in 8-K/A - Stock Titan
BOLD SEC FilingsBOUNDLESS BIO INC 10-K, 10-Q, 8-K Forms - Stock Titan
TRML SEC FilingsTourmaline Bio 10-K, 10-Q, 8-K Forms - Stock Titan
New CyPath Lung validation study at BAMC by bioAffinity (BIAF) - Stock Titan
TELA SEC FilingsTela Bio, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Gossamer Bio (GOSS) Downgraded by Wedbush with Significant PT Reduction | GOSS Stock News - GuruFocus
BioMarin’s top execs schedule four investor events in March - Stock Titan
Construction giant brings drug tests in-house with fingerprint scans at UK sites - Stock Titan
BIO-key to secure Mozambique digital payments for 36.6M people - Stock Titan
Bio-Path (BPTH) grants CEO affiliate new preferred shares and weighs trial restarts - Stock Titan
Axsome Therapeutics, Inc. SEC 10-K Report - TradingView
BioMarin (BMRN) grows 2025 revenue 13% and guides 2026 EPS to $4.95–$5.15 - Stock Titan
Inclement weather delays PROCEPT BioRobotics Q4 call, Investor Day - Stock Titan
Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash? - Stocktwits
INmune Bio Inc. Announces Webinar on XPro1595 Registrational Pathway for Early Alzheimer's Disease Treatment - Quiver Quantitative
Alzheimer’s therapy XPro1595 nears key trial as INmune Bio details Phase 3 path - Stock Titan
Gossamer Bio reports PROSERA topline: missed primary 6MWD endpoint but secondary endpoints and high-risk subgroup favored seralutinib - TradingView
Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension - Business Wire
Zura Bio (ZURA) appoints Mark Eisner and Ajay Nirula to its board - Stock Titan
Gossamer Bio (GOSS) Phase 3 PROSERA miss offsets strong seralutinib subgroup data - Stock Titan
In 8 Bio Inc Stock (INAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.02%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):